GSK's ovarian cancer treatment meets main goal in late-stage study

Credit: REUTERS/Loriene Perera

GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

July 15 (Reuters) - GlaxoSmithKline GSK.L said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.

The drugmaker said the study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Arun Koyyur)

((noor.hussain@thomsonreuters.com; Within UK +44 20 7542 1810; Outside UK +91 80 6749 2764; Reuters Messaging: noor.hussain.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More